Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Approximately 13% of boys with Duchenne muscular dystrophy (DMD) have a nonsense mutation in the dystrophin gene, resulting in a premature stop codon in the corresponding mRNA and failure to generate a functional protein. Ataluren (PTC124) enables ribosomal readthrough of premature stop codons, leading to production of full-length, functional proteins. METHODS: This Phase 2a open-label, sequential dose-ranging trial recruited 38 boys with nonsense mutation DMD. The first cohort (n = 6) received ataluren three times per day at morning, midday, and evening doses of 4, 4, and 8 mg/kg; the second cohort (n = 20) was dosed at 10, 10, 20 mg/kg; and the third cohort (n = 12) was dosed at 20, 20, 40 mg/kg. Treatment duration was 28 days. Change in full-length dystrophin expression, as assessed by immunostaining in pre- and post-treatment muscle biopsy specimens, was the primary endpoint. FINDINGS: Twenty three of 38 (61%) subjects demonstrated increases in post-treatment dystrophin expression in a quantitative analysis assessing the ratio of dystrophin/spectrin. A qualitative analysis also showed positive changes in dystrophin expression. Expression was not associated with nonsense mutation type or exon location. Ataluren trough plasma concentrations active in the mdx mouse model were consistently achieved at the mid- and high- dose levels in participants. Ataluren was generally well tolerated. INTERPRETATION: Ataluren showed activity and safety in this short-term study, supporting evaluation of ataluren 10, 10, 20 mg/kg and 20, 20, 40 mg/kg in a Phase 2b, double-blind, long-term study in nonsense mutation DMD. TRIAL REGISTRATION: ClinicalTrials.gov NCT00264888.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Procedures for Detecting Outlying Observations in Samples
Grubbs, F. E. (1969) · Technometrics · doi:10.1080/00401706.1969.10490657 · Cited by 4,105 · cited 1×
“The 24hour concentration of one subject in the 20, 20, 40 mg/kg dose group was excluded from all pharmacokinetic analyses because his value at the 24-hour timepoint on Day 1 (171 mg/mL) was as an outlier based on the Grubbs statistical outlier test [14].”
MethodPTC124 targets genetic disorders caused by nonsense mutations
Welch, E. M., Barton, E. R., Zhuo, J., Tomizawa, Y., Friesen, W. J., Trifillis, P., Paushkin, S., Patel, M., Trotta, C. R., Hwang, S., et al. (2007) · Nature · doi:10.1038/nature05756 · Cited by 1,137 · cited 3×
“[3,4] We and others have shown that ataluren is active in multiple cell-based and animal disease models.”
BackgroundSelf-citationCirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M. E., Bourke, J., Wells, D. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60756-3 · Cited by 878 · cited 1×
“[17,18] Western blotting analysis was not conducted in this study because there was insufficient biopsy material remaining, post-immunostaining, to perform Western blot analysis.”
Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy
Goemans, N. M., Tulinius, M., van den Akker, J. T., Burm, B. E., Ekhart, P. F., Heuvelmans, N., Holling, T., Janson, A. A., Platenburg, G. J., Sipkens, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011367 · Cited by 678 · cited 1×
“[17,18] Western blotting analysis was not conducted in this study because there was insufficient biopsy material remaining, post-immunostaining, to perform Western blot analysis.”
MethodThe 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy
McDonald, C. M., Henricson, E. K., Han, J. J., Abresch, R. T., Nicorici, A., Elfring, G. L., Atkinson, L., Reha, A., Hirawat, S., & Miller, L. L. (2010) · Muscle & Nerve · doi:10.1002/mus.21544 · Cited by 397 · cited 1×
“Ultimately, clinically meaningful outcome measures such as the 6-minute walk test are required to evaluate therapeutic benefit in DMD [20,21].”
BackgroundSelf-citationDu, M., Liu, X., Welch, E. M., Hirawat, S., Peltz, S. W., & Bedwell, D. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711795105 · Cited by 256
Self-citationHirawat, S., Welch, E. M., Elfring, G. L., Northcutt, V. J., Paushkin, S., Hwang, S., Leonard, E. M., Almstead, N. G., Ju, W., Peltz, S. W., et al. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006297140 · Cited by 242
Self-citationMizuno, H., Nakamura, A., Aoki, Y., Ito, N., Kishi, S., Yamamoto, K., Sekiguchi, M., Takeda, S., & Hashido, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018388 · Cited by 198 · cited 1×
“[15,19] Given the limitations in current quantitative dystrophin assays and CK, a validated biomarker for monitoring of drug activity in DMD is needed to facilitate drug development in this disease.”
BackgroundThe 6‐minute walk test in Duchenne/Becker muscular dystrophy: Longitudinal observations
MCDonald, C. M., Henricson, E. K., Han, J. J., Abresch, R. T., Nicorici, A., Atkinson, L., Elfring, G. L., Reha, A., & Miller, L. L. (2010) · Muscle & Nerve · doi:10.1002/mus.21808 · Cited by 172 · cited 1×
“Ultimately, clinically meaningful outcome measures such as the 6-minute walk test are required to evaluate therapeutic benefit in DMD [20,21].”
BackgroundSelf-citationImproved molecular diagnosis of dystrophinopathies in an unselected clinical cohort
Dent, K. M., Dunn, D. M., von Niederhausern, A. C., Aoyagi, A., Kerr, L. M., Bromberg, M. B., Hart, K., Tuohy, T. M. F., White, S. J., den Dunnen, J. T., et al. (2005) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30617 · Cited by 170 · cited 1×
“Nonsense mutations are responsible for approximately 13% of DMD cases [2].”
BackgroundSelf-citationLinde, L., Boelz, S., Neu‐Yilik, G., Kulozik, A. E., & Kerem, B. (2007) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201889 · Cited by 155 · cited 1×
“[22] Down regulating NMD by reducing UPF1 or UPF2 levels increased chloride channel activity in response to gentamicin in cell culture, consistent with the notion that transcript levels may act as a disease modifier.”
BackgroundNadarajah, V. D., van Putten, M., Chaouch, A., Garrood, P., Straub, V. W., Lochmüller, H., Ginjaar, H. B., Aartsma-Rus, A. M., van Ommen, G. B., den Dunnen, J. T., et al. (2011) · Neuromuscular Disorders · doi:10.1016/j.nmd.2011.05.011 · Cited by 155 · cited 2×
“[15] Typically, a bilateral muscle is sampled from one side of the body before treatment and from the other side after treatment; thus, any differences between the left and right muscles introduce variability.”
BackgroundKayalı, R., Ku, J., Khitrov, G., Jung, M. E., Приходько, О. О., & Bertoni, C. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds223 · Cited by 116
PTC124-Mediated Translational Readthrough of a Nonsense Mutation Causing Usher Syndrome Type 1C
Goldmann, T., Overlack, N., Wolfrum, U., & Nagel‐Wolfrum, K. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.067 · Cited by 104
Stedman, H. H., Wilson, J. M., Finke, R., Kleckner, A. L., & Mendell, J. R. (2000) · Human Gene Therapy · doi:10.1089/10430340050015671 · Cited by 82
Emerging genetic therapies to treat Duchenne muscular dystrophy
Nelson, S. F., Crosbie, R. H., Miceli, M. C., & Spencer, M. J. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32832fd487 · Cited by 72 · cited 1×
“Strategies in clinical trials to restore dystrophin in muscle cell membranes include nonsense mutation suppression and exon skipping [1].”
BackgroundWang, D., Shukla, C., Liu, X., Schoeb, T. R., Clarke, L. A., Bedwell, D. M., & Keeling, K. M. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.08.002 · Cited by 62 · cited 1×
“[3–9] Phase 1 studies in healthy volunteers established the initial ataluren safety profile [10] and defined dosing regimens for achieving target trough plasma concentrations (2 to 10 mg/mL) known to be active in preclinical models [3,5].”
BackgroundSarkar, C., Zhang, Z., & Mukherjee, A. B. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.05.021 · Cited by 62 · cited 1×
“[3–9] Phase 1 studies in healthy volunteers established the initial ataluren safety profile [10] and defined dosing regimens for achieving target trough plasma concentrations (2 to 10 mg/mL) known to be active in preclinical models [3,5].”
BackgroundQuantification of dystrophin immunofluorescence in dystrophinopathy muscle specimens
Taylor, L. E., Kaminoh, Y., Rodesch, C. K., & Flanigan, K. M. (2012) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2012.01250.x · Cited by 59 · cited 1×
“[16] Different methods (eg immunostaining and Western blot) applied to the same specimens result in inconsistent dystrophin levels.”
MethodSelf-citationPTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutation
Tan, L., Narayan, S. B., Chen, J., Meyers, G. D., & Bennett, M. J. (2011) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9265-5 · Cited by 42 · cited 1×
“[3–9] Phase 1 studies in healthy volunteers established the initial ataluren safety profile [10] and defined dosing regimens for achieving target trough plasma concentrations (2 to 10 mg/mL) known to be active in preclinical models [3,5].”
Background
Cited by
McDonald, C. M., Campbell, C., Torricelli, R. E., Finkel, R. S., Flanigan, K. M., Goemans, N., Heydemann, P., Kaminska, A., Kirschner, J., Muntoni, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31611-2 · Cited by 452
Self-citationAtaluren treatment of patients with nonsense mutation dystrophinopathy
Bushby, K., Finkel, R., Wong, B., Barohn, R., Campbell, C., Comi, G. P., Connolly, A. M., Day, J. W., Flanigan, K. M., Goemans, N., et al. (2014) · Muscle & Nerve · doi:10.1002/mus.24332 · Cited by 428
Self-citationAllen, D. G., Whitehead, N. P., & Froehner, S. C. (2016) · Physiological Reviews · doi:10.1152/physrev.00007.2015 · Cited by 426
Nonsense-mediated mRNA decay in humans at a glance
Kurosaki, T., & Maquat, L. E. (2016) · Journal of Cell Science · doi:10.1242/jcs.181008 · Cited by 396
“…along the drug-development pipeline, as it has shown the greatest effectiveness in treating Duchenne muscular dystrophy caused by nonsense mutations, but at doses that do not detectably inhibit NMD, consistent with its mild effects on cellular metabolism (Finkel et al., 2013; Welch et al., 2007).”
BackgroundDuchenne and Becker Muscular Dystrophies
Flanigan, K. M. (2014) · Neurologic Clinics · doi:10.1016/j.ncl.2014.05.002 · Cited by 317
Self-citation
Metadata
- Authors
- Finkel, R. S., Flanigan, K. M., Wong, B., Bönnemann, C., Sampson, J., Sweeney, H. L., Reha, A., Northcutt, V. J., Elfring, G., Barth, J., & Peltz, S. W.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-12-11
- Volume
- 8
- Issue
- 12
- Pages
- e81302
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2035041709
- Cited by
- 246
- References
- 20
- FWCI
- 10.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.